ACTU
hierRésumé IA
China's Domestic Novel Drugs Dominate H1 Market Approvals, Signaling Innovation Leap
China's market approvals in the first half of the year were dominated by domestically produced novel drugs, accounting for over 80% of clearances. This includes CARsgen Therapeutics' Satri-cel, the world's first CAR-T treatment for solid tumors, and Neuracle Medical Technology's implantable brain-computer interface system.
S
SCMP Economy1 min de lecture